Abstract
β-Glucans are cell wall constituents of many plants and microorganisms. However, β-glucans are not expressed on mammalian cells and are recognized as pathogen-associated molecular patterns by pattern recognition receptors. β- Glucans have been used to treat cancer and infectious disease for many years as biological response modifiers with varying and unpredictable efficacy. Recent studies have demonstrated the mechanism of action of yeast-derived β-glucan in combination with anti-tumor monoclonal antibodies in cancer therapy. in vitro and in vivo Data indicate that successful combination therapy requires complement activation and iC3b deposition on tumors and complement receptor 3 (CR3) expression on granulocytes. The defined effector cells are CR3+ neutrophils. This review provides a brief overview of this combination therapy in cancer and describes in detail the β-glucan composition and receptors, mechanism of action, and preclinical studies in human carcinoma xenograft models. Current and future developments are also discussed to provide our own point of view on this combination therapy in potential clinical investigations. Relevant patents are discussed.
Keywords: Anti-tumor monoclonal antibody, β-glucan, immunotherapy, complement receptor, neutrophils, complement regulatory proteins
Recent Patents on Anti-Cancer Drug Discovery
Title: Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer
Volume: 4 Issue: 2
Author(s): Jingjing Liu, Lacey Gunn, Richard Hansen and Jun Yan
Affiliation:
Keywords: Anti-tumor monoclonal antibody, β-glucan, immunotherapy, complement receptor, neutrophils, complement regulatory proteins
Abstract: β-Glucans are cell wall constituents of many plants and microorganisms. However, β-glucans are not expressed on mammalian cells and are recognized as pathogen-associated molecular patterns by pattern recognition receptors. β- Glucans have been used to treat cancer and infectious disease for many years as biological response modifiers with varying and unpredictable efficacy. Recent studies have demonstrated the mechanism of action of yeast-derived β-glucan in combination with anti-tumor monoclonal antibodies in cancer therapy. in vitro and in vivo Data indicate that successful combination therapy requires complement activation and iC3b deposition on tumors and complement receptor 3 (CR3) expression on granulocytes. The defined effector cells are CR3+ neutrophils. This review provides a brief overview of this combination therapy in cancer and describes in detail the β-glucan composition and receptors, mechanism of action, and preclinical studies in human carcinoma xenograft models. Current and future developments are also discussed to provide our own point of view on this combination therapy in potential clinical investigations. Relevant patents are discussed.
Export Options
About this article
Cite this article as:
Liu Jingjing, Gunn Lacey, Hansen Richard and Yan Jun, Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (2) . https://dx.doi.org/10.2174/157489209788452858
DOI https://dx.doi.org/10.2174/157489209788452858 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondria as Targets for Neuronal Protection Against Excitotoxicity: A Role for Phenolic Compounds?
Central Nervous System Agents in Medicinal Chemistry β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders
Current Pharmaceutical Design MicroRNAs: Emerging Role in the Endogenous μ Opioid System
CNS & Neurological Disorders - Drug Targets Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets Resisting the Resistance in Cancer: Cheminformatics Studies on Short- Path Base Excision Repair Pathway Antagonists Using Supervised Learning Approaches
Combinatorial Chemistry & High Throughput Screening Beta-Amyloid, Oxidative Stress and Down Syndrome
Current Alzheimer Research Herbal Resources to Combat a Progressive & Degenerative Nervous System Disorder- Parkinson’s Disease
Current Drug Targets Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Natural Coumarins as a Novel Class of Neuroprotective Agents
Mini-Reviews in Medicinal Chemistry Targeting Calcium Channels to Block Tumor Vascularization
Recent Patents on Anti-Cancer Drug Discovery Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications
Current Medicinal Chemistry Novel Approaches for Modulating dUTPase and Uracil-DNA Glycosylase: Potential Uses for Cancer and Viral Chemotherapy
Drug Design Reviews - Online (Discontinued) Prion Protein Misfolding and Brain Degeneration
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Biosafety of Herpesvirus Vectors
Current Gene Therapy Biocompatible Micelles Based on Squalene Portions Linked to PEGylated Polyaspartamide as Potential Colloidal Drug Carriers
Current Nanoscience